New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome

References

• Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome?. Immunobiology 2012; 217:235 - 43; http://dx.doi.org/10.1016/j.imbio.2011.07.022; PMID: 21852019
   PubMed Web of Science ®Google Scholar
• Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45:531 - 6; http://dx.doi.org/10.1038/ng.2590; PMID: 23542698
   PubMed Web of Science ®Google Scholar
• Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676 - 87; http://dx.doi.org/10.1056/NEJMra0902814; PMID: 19846853
   PubMed Web of Science ®Google Scholar
• Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl 2009; Suppl S4 - 7; http://dx.doi.org/10.1038/ki.2008.608; PMID: 19180132
   PubMedGoogle Scholar
• Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl 2009; Suppl S17 - 9; http://dx.doi.org/10.1038/ki.2008.612; PMID: 19180125
   PubMedGoogle Scholar
• Petruzziello-Pellegrini TN, Marsden PA. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 2012; 21:433 - 40; http://dx.doi.org/10.1097/MNH.0b013e328354a62e; PMID: 22660553
   PubMed Web of Science ®Google Scholar
• Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1:619 - 20; http://dx.doi.org/10.1016/S0140-6736(83)91795-6; PMID: 6131302
   PubMed Web of Science ®Google Scholar
• Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151:775 - 82; http://dx.doi.org/10.1093/infdis/151.5.775; PMID: 3886804
   PubMed Web of Science ®Google Scholar
• Jerse AE, Yu J, Tall BD, Kaper JB. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A 1990; 87:7839 - 43; http://dx.doi.org/10.1073/pnas.87.20.7839; PMID: 2172966
   PubMed Web of Science ®Google Scholar
• Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073 - 86; PMID: 15781103
   PubMed Web of Science ®Google Scholar
• Karmali MA, Gannon V, Sargeant JM. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol 2010; 140:360 - 70; http://dx.doi.org/10.1016/j.vetmic.2009.04.011; PMID: 19410388
   PubMed Web of Science ®Google Scholar
• Warshawsky B, Gutmanis I, Henry B, Dow J, Reffle J, Pollett G, Ahmed R, Aldom J, Alves D, Chagla A, et al. Outbreak of Escherichia coli 0157:H7 related to animal contact at a petting zoo. Can J Infect Dis 2002; 13:175 - 81; PMID: 18159389
   PubMedGoogle Scholar
• Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23:1749 - 60; http://dx.doi.org/10.1007/s00467-008-0935-6; PMID: 18704506
   PubMed Web of Science ®Google Scholar
• Obrig TG. Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) 2010; 2:2769 - 94; http://dx.doi.org/10.3390/toxins2122769; PMID: 21297888
   PubMed Web of Science ®Google Scholar
• Jansen A, Kielstein JT. The new face of enterohaemorrhagic Escherichia coli infections. Euro Surveill 2011; 16:19898; PMID: 21722615
   PubMedGoogle Scholar
• Petruzziello-Pellegrini TN, Yuen DA, Page AV, Patel S, Soltyk AM, Matouk CC, Wong DK, Turgeon PJ, Fish JE, Ho JJ, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 2012; 122:759 - 76; http://dx.doi.org/10.1172/JCI57313; PMID: 22232208
   PubMed Web of Science ®Google Scholar
• Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012; 8:658 - 69; http://dx.doi.org/10.1038/nrneph.2012.196; PMID: 22986362
   PubMed Web of Science ®Google Scholar
• Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511 - 8; http://dx.doi.org/10.1016/S0022-3476(94)70001-X; PMID: 7931868
   PubMed Web of Science ®Google Scholar
• Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25:2231 - 40; http://dx.doi.org/10.1007/s00467-010-1522-1; PMID: 20424866
   PubMed Web of Science ®Google Scholar
• Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; In press http://dx.doi.org/10.1007/s00467-012-2383-6; PMID: 23288350
   PubMed Web of Science ®Google Scholar
• Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H, German-Austrian HUS Study Group. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54:1413 - 21; http://dx.doi.org/10.1093/cid/cis196; PMID: 22412065
   PubMed Web of Science ®Google Scholar
• Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365:709 - 17; http://dx.doi.org/10.1056/NEJMoa1106920; PMID: 21793740
   PubMed Web of Science ®Google Scholar
• Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55:33 - 41; http://dx.doi.org/10.1093/cid/cis299; PMID: 22431799
   PubMed Web of Science ®Google Scholar
• Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56:3277 - 82; http://dx.doi.org/10.1128/AAC.06315-11; PMID: 22391549
   PubMed Web of Science ®Google Scholar
• Tarr PI, Karpman D. Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins. Clin Infect Dis 2012; 55:760 - 3; http://dx.doi.org/10.1093/cid/cis533; PMID: 22670035
   PubMed Web of Science ®Google Scholar
• Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089 - 93; http://dx.doi.org/10.1016/S0140-6736(11)61145-8; PMID: 21871657
   PubMed Web of Science ®Google Scholar
• Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115:e673 - 80; http://dx.doi.org/10.1542/peds.2004-2236; PMID: 15930195
   PubMedGoogle Scholar
• Ullrich S, Bremer P, Neumann-Grutzeck C, Otto H, Rüther C, von Seydewitz CU, Meyer GP, Ahmadi-Simab K, Röther J, Hogan B, et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS One 2013; 8:e55278; http://dx.doi.org/10.1371/journal.pone.0055278; PMID: 23460784
   PubMedGoogle Scholar
• Johannes L, Römer W. Shiga toxins--from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8:105 - 16; PMID: 20023663
   PubMed Web of Science ®Google Scholar
• Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, et al, HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771 - 80; http://dx.doi.org/10.1056/NEJMoa1106483; PMID: 21696328
   PubMed Web of Science ®Google Scholar
• Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der Heiden M, Adlhoch C, Dreesman J, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365:1763 - 70; http://dx.doi.org/10.1056/NEJMoa1106482; PMID: 22029753
   PubMed Web of Science ®Google Scholar
• Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010; 8:26 - 38; PMID: 19966814
   PubMed Web of Science ®Google Scholar
• Scheutz F, Nielsen EM, Frimodt-Møller J, Boisen N, Morabito S, Tozzoli R, Nataro JP, Caprioli A. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. Euro Surveill 2011; 16:19889; PMID: 21699770
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control and European Food Safety Authority. Shiga toxin/verotoxin-producing Escherichia coli in humans, food and animals in the EU/EEA, with special reference to the German outbreak strain STEC O104. Stockholm: ECDC, 2011.
   Google Scholar
• Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, Peters G, Karch H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11:671 - 6; PMID: 21703928
   PubMed Web of Science ®Google Scholar
• Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One 2011; 6:e22751; http://dx.doi.org/10.1371/journal.pone.0022751; PMID: 21799941
   PubMed Web of Science ®Google Scholar
• Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, Chen W, Pu F, Peng Y, Li J, et al, E. coli O104:H4 Genome Analysis Crowd-Sourcing Consortium. Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med 2011; 365:718 - 24; http://dx.doi.org/10.1056/NEJMoa1107643; PMID: 21793736
   PubMed Web of Science ®Google Scholar
• Grad YH, Godfrey P, Cerquiera GC, Mariani-Kurkdjian P, Gouali M, Bingen E, Shea TP, Haas BJ, Griggs A, Young S, et al. Comparative genomics of recent Shiga toxin-producing Escherichia coli O104:H4: short-term evolution of an emerging pathogen. MBio 2013; 4:e00452 - 12; http://dx.doi.org/10.1128/mBio.00452-12; PMID: 23341549
   PubMedGoogle Scholar
• Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012; 50:2951 - 63; http://dx.doi.org/10.1128/JCM.00860-12; PMID: 22760050
   PubMed Web of Science ®Google Scholar
• Scotland SM, Smith HR, Willshaw GA, Rowe B. Vero cytotoxin production in strain of Escherichia coli is determined by genes carried on bacteriophage. Lancet 1983; 2:216; http://dx.doi.org/10.1016/S0140-6736(83)90192-7; PMID: 6135046
   PubMed Web of Science ®Google Scholar
• O’Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 1984; 226:694 - 6; http://dx.doi.org/10.1126/science.6387911; PMID: 6387911
   PubMed Web of Science ®Google Scholar
• Newland JW, Strockbine NA, Miller SF, O’Brien AD, Holmes RK. Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli. Science 1985; 230:179 - 81; http://dx.doi.org/10.1126/science.2994228; PMID: 2994228
   PubMed Web of Science ®Google Scholar
• Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998; 101:372 - 82; http://dx.doi.org/10.1172/JCI522; PMID: 9435309
   PubMed Web of Science ®Google Scholar
• Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect. FEBS Lett 2010; 584:1879 - 86; http://dx.doi.org/10.1016/j.febslet.2009.11.089; PMID: 19948172
   PubMed Web of Science ®Google Scholar
• Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993; 268:15484 - 8; PMID: 8340376
   PubMed Web of Science ®Google Scholar
• Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171:45 - 50; http://dx.doi.org/10.1111/j.1432-1033.1988.tb13756.x; PMID: 3276522
   PubMedGoogle Scholar
• Saxena SK, O’Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 1989; 264:596 - 601; PMID: 2642481
   PubMed Web of Science ®Google Scholar
• Furutani M, Kashiwagi K, Ito K, Endo Y, Igarashi K. Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin. Arch Biochem Biophys 1992; 293:140 - 6; http://dx.doi.org/10.1016/0003-9861(92)90376-8; PMID: 1731630
   PubMed Web of Science ®Google Scholar
• Obrig TG, Moran TP, Brown JE. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 1987; 244:287 - 94; PMID: 3663122
   PubMed Web of Science ®Google Scholar
• Karpman D, Håkansson A, Perez MT, Isaksson C, Carlemalm E, Caprioli A, Svanborg C. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998; 66:636 - 44; PMID: 9453620
   PubMed Web of Science ®Google Scholar
• Jones NL, Islur A, Haq R, Mascarenhas M, Karmali MA, Perdue MH, Zanke BW, Sherman PM. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 2000; 278:G811 - 9; PMID: 10801274
   PubMedGoogle Scholar
• Suzuki A, Doi H, Matsuzawa F, Aikawa S, Takiguchi K, Kawano H, Hayashida M, Ohno S. Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between bcl-2 and tissue failure by E. coli O157:H7. Genes Dev 2000; 14:1734 - 40; PMID: 10898788
   PubMed Web of Science ®Google Scholar
• Tesh VL. The induction of apoptosis by Shiga toxins and ricin. Curr Top Microbiol Immunol 2012; 357:137 - 78; http://dx.doi.org/10.1007/82_2011_155; PMID: 22130961
   PubMed Web of Science ®Google Scholar
• Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158 - 73; http://dx.doi.org/10.1161/01.RES.0000255691.76142.4a; PMID: 17272818
   PubMed Web of Science ®Google Scholar
• Aird WC. Endothelium in health and disease. Pharmacol Rep 2008; 60:139 - 43; PMID: 18276995
   PubMed Web of Science ®Google Scholar
• Matussek A, Lauber J, Bergau A, Hansen W, Rohde M, Dittmar KE, Gunzer M, Mengel M, Gatzlaff P, Hartmann M, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003; 102:1323 - 32; http://dx.doi.org/10.1182/blood-2002-10-3301; PMID: 12702508
   PubMed Web of Science ®Google Scholar
• Louise CB, Obrig TG. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res 1994; 47:377 - 87; http://dx.doi.org/10.1006/mvre.1994.1030; PMID: 8084301
   PubMed Web of Science ®Google Scholar
• Nestoridi E, Tsukurov O, Kushak RI, Ingelfinger JR, Grabowski EF. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 2005; 3:752 - 62; http://dx.doi.org/10.1111/j.1538-7836.2005.01205.x; PMID: 15842359
   PubMed Web of Science ®Google Scholar
• Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261:600 - 3; http://dx.doi.org/10.1126/science.8342023; PMID: 8342023
   PubMed Web of Science ®Google Scholar
• Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995; 28:495 - 500; http://dx.doi.org/10.1006/geno.1995.1180; PMID: 7490086
   PubMed Web of Science ®Google Scholar
• Takabatake Y, Sugiyama T, Kohara H, Matsusaka T, Kurihara H, Koni PA, Nagasawa Y, Hamano T, Matsui I, Kawada N, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 2009; 20:1714 - 23; http://dx.doi.org/10.1681/ASN.2008060640; PMID: 19443644
   PubMed Web of Science ®Google Scholar
• Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393:591 - 4; http://dx.doi.org/10.1038/31261; PMID: 9634237
   PubMed Web of Science ®Google Scholar
• Lévesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187 - 96; PMID: 12531874
   PubMed Web of Science ®Google Scholar
• Panicot-Dubois L, Thomas GM, Furie BC, Furie B, Lombardo D, Dubois C. Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 2007; 117:3708 - 19; http://dx.doi.org/10.1172/JCI32655; PMID: 18037996
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858 - 64; http://dx.doi.org/10.1038/nm1075; PMID: 15235597
   PubMed Web of Science ®Google Scholar
• Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12:557 - 67; http://dx.doi.org/10.1038/nm1400; PMID: 16648859
   PubMed Web of Science ®Google Scholar
• Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115:5102 - 10; http://dx.doi.org/10.1182/blood-2009-07-230284; PMID: 20154215
   PubMed Web of Science ®Google Scholar
• Ruiz de Almodovar C, Luttun A, Carmeliet P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell 2006; 124:18 - 21; http://dx.doi.org/10.1016/j.cell.2005.12.023; PMID: 16413476
   PubMed Web of Science ®Google Scholar
• Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97:937 - 45; http://dx.doi.org/10.1182/blood.V97.4.937; PMID: 11159520
   PubMed Web of Science ®Google Scholar
• Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346:23 - 32; http://dx.doi.org/10.1056/NEJMoa011033; PMID: 11777999
   PubMed Web of Science ®Google Scholar
• Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106:4199 - 209; http://dx.doi.org/10.1182/blood-2005-05-2111; PMID: 16131569
   PubMed Web of Science ®Google Scholar
• Morigi M, Zoja C, Figliuzzi M, Foppolo M, Micheletti G, Bontempelli M, Saronni M, Remuzzi G, Remuzzi A. Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood 1995; 85:1696 - 703; PMID: 7535583
   PubMed Web of Science ®Google Scholar
• Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A, Zoja C, Remuzzi G. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001; 98:1828 - 35; http://dx.doi.org/10.1182/blood.V98.6.1828; PMID: 11535517
   PubMed Web of Science ®Google Scholar
• Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, te Loo M, Monnens L, Remuzzi G, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002; 62:846 - 56; http://dx.doi.org/10.1046/j.1523-1755.2002.00503.x; PMID: 12164866
   PubMed Web of Science ®Google Scholar
• Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61:3886 - 91; PMID: 8359910
   PubMed Web of Science ®Google Scholar
• Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 2010; 19:242 - 7; http://dx.doi.org/10.1097/MNH.0b013e3283378f25; PMID: 20186056
   PubMed Web of Science ®Google Scholar
• Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394 - 400; http://dx.doi.org/10.4049/jimmunol.0900151; PMID: 19414792
   PubMed Web of Science ®Google Scholar
• Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1920 - 4; http://dx.doi.org/10.2215/CJN.02730409; PMID: 19820137
   PubMed Web of Science ®Google Scholar
• Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503 - 13; http://dx.doi.org/10.1182/blood-2010-09-309161; PMID: 21447825
   PubMed Web of Science ®Google Scholar
• Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187:172 - 80; http://dx.doi.org/10.4049/jimmunol.1100491; PMID: 21642543
   PubMed Web of Science ®Google Scholar
• Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561 - 3; http://dx.doi.org/10.1056/NEJMc1100859; PMID: 21612462
   PubMed Web of Science ®Google Scholar
• Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8:622 - 33; http://dx.doi.org/10.1038/nrneph.2012.195; PMID: 22986360
   PubMed Web of Science ®Google Scholar
• Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, et al, EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565; http://dx.doi.org/10.1136/bmj.e4565; PMID: 22815429
   PubMedGoogle Scholar
• Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, et al, Collaborators of the DGfN STEC-HUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012; 27:3807 - 15; http://dx.doi.org/10.1093/ndt/gfs394; PMID: 23114903
   PubMed Web of Science ®Google Scholar
• Page AV, Tarr PI, Watkins SL, Rajwans N, Petruzziello-Pellegrini TN, Marsden PA, Kain KC, Liles WC. Dysregulation of Angiopoietin 1 and 2 in Escherichia coli O157:H7 Infection and the Hemolytic-Uremic Syndrome. J Infect Dis 2013; 208:929 - 33; http://dx.doi.org/10.1093/infdis/jit268; PMID: 23801605
   PubMed Web of Science ®Google Scholar